Impact of antiviral treatment on long-term prognosis in non-immunocompromised patients with CMV reactivation

Reactivation of human cytomegalovirus (CMV) occurs in non-immunocompromised patients with or without specific organ involvement, but it is still unknown whether it has a clinical implication on long-term prognosis or not. A retrospective cohort study evaluating non-immunocompromised adult patients w...

Full description

Saved in:
Bibliographic Details
Published in:BMC infectious diseases 2021-05, Vol.21 (1), p.414-414, Article 414
Main Authors: Park, Ga Eun, Ki, Hyun Kyun, Ko, Jae-Hoon
Format: Article
Language:English
Subjects:
Antiviral drugs
Bacterial infections
Cytomegalovirus
Disease
Drug dosages
Ganciclovir
Genetic testing
HIV
Hospitalization
Hospitals
Human immunodeficiency virus
Illnesses
Immunocompromised hosts
Infections
Length of stay
Long-term
Medical prognosis
Mortality
Multivariate analysis
Pathogens
Patients
Prognosis
Reactivation
Survival
Ventilators
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c496t-e19a237996584662842d7e2c4a333e9d45bc4718bbe3419c10f1cd96a8adc7033
cites cdi_FETCH-LOGICAL-c496t-e19a237996584662842d7e2c4a333e9d45bc4718bbe3419c10f1cd96a8adc7033
container_end_page 414
container_issue 1
container_start_page 414
container_title BMC infectious diseases
container_volume 21
creator Park, Ga Eun
Ki, Hyun Kyun
Ko, Jae-Hoon
description Reactivation of human cytomegalovirus (CMV) occurs in non-immunocompromised patients with or without specific organ involvement, but it is still unknown whether it has a clinical implication on long-term prognosis or not. A retrospective cohort study evaluating non-immunocompromised adult patients with CMV reactivation was conducted during the period between January 2010 and February 2018. Patients were divided into ganciclovir-treated and non-treated groups. Patients who died within 30 days from CMV reactivation were excluded as they died from complex causes of conditions. Survivors were followed for 30-months to evaluate long-term prognosis. A total of 136 patients with CMV reactivation was included, consisting of 66 ganciclovir-treated (48.5%) and 70 non-treated (51.5%) patients. Overall, patients were old-aged (median 70 years old) and most were treated with pneumonia of any cause (91.2%). More patients in ganciclovir-treated group were treated at intensive care unit (43.9% vs 24.3%, respectively) and had higher viral load over 5000 copies/ml (48.5% vs 22.9%) than non-treated group (all P 
doi_str_mv 10.1186/s12879-021-06098-4
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_a10e3fe881134dce86e78ca5a235aad3</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_a10e3fe881134dce86e78ca5a235aad3</doaj_id><sourcerecordid>2528869448</sourcerecordid><originalsourceid>FETCH-LOGICAL-c496t-e19a237996584662842d7e2c4a333e9d45bc4718bbe3419c10f1cd96a8adc7033</originalsourceid><addsrcrecordid>eNpdkk1v1DAQhiMEoqXwBzggS1y4BPyV2L4goRUfKxVxAa7WrDPZepXYwXaK-Pd4u6VqOdmaeefRzKu3aV4y-pYx3b_LjGtlWspZS3tqdCsfNedMKtZyIeTje_-z5lnOB0qZ0tw8bc6EMFIJ0Z0303ZewBUSRwKh-GufYCIlIZQZQy0HMsWwbwummSwp7kPMPhMfSIih9fO8hujiXDuzzziQBYqvc5n89uWKbL7-JBXlKrfWY3jePBlhyvji9r1ofnz6-H3zpb389nm7-XDZOmn60iIzwIUypu-07HuuJR8UcidBCIFmkN3O1cv0bodCMuMYHZkbTA8aBqeoEBfN9sQdIhzskvwM6Y-N4O1NIaa9hVS8m9ACoyhG1JoxIQeHukelHXR1gQ5gOLLen1jLupuxKkKpFj2APuwEf2X38dpqamSnjoA3t4AUf62Yi61WOZwmCBjXbHnHuTBGcFalr_-THuKaQrXqqNK6N1LqquInlUsx54Tj3TKM2mMw7CkYtgbD3gTDyjr06v4ZdyP_kiD-AgR6tcc</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2528869448</pqid></control><display><type>article</type><title>Impact of antiviral treatment on long-term prognosis in non-immunocompromised patients with CMV reactivation</title><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><source>NCBI_PubMed Central（免费）</source><creator>Park, Ga Eun ; Ki, Hyun Kyun ; Ko, Jae-Hoon</creator><creatorcontrib>Park, Ga Eun ; Ki, Hyun Kyun ; Ko, Jae-Hoon</creatorcontrib><description>Reactivation of human cytomegalovirus (CMV) occurs in non-immunocompromised patients with or without specific organ involvement, but it is still unknown whether it has a clinical implication on long-term prognosis or not. A retrospective cohort study evaluating non-immunocompromised adult patients with CMV reactivation was conducted during the period between January 2010 and February 2018. Patients were divided into ganciclovir-treated and non-treated groups. Patients who died within 30 days from CMV reactivation were excluded as they died from complex causes of conditions. Survivors were followed for 30-months to evaluate long-term prognosis. A total of 136 patients with CMV reactivation was included, consisting of 66 ganciclovir-treated (48.5%) and 70 non-treated (51.5%) patients. Overall, patients were old-aged (median 70 years old) and most were treated with pneumonia of any cause (91.2%). More patients in ganciclovir-treated group were treated at intensive care unit (43.9% vs 24.3%, respectively) and had higher viral load over 5000 copies/ml (48.5% vs 22.9%) than non-treated group (all P &lt; 0.05). Primary and secondary endpoints including 30-months survival (28.0 vs 38.9%, respectively) and 12-months survival (40.3% vs 49.2%) were not statistically different between the ganciclovir-treated and non-treated groups. In the multivariate analyses, ganciclovir treatment was not associated with 30-months survival (HR 1.307, 95% CI 0.759-2.251) and 12-months survival (HR 1.533, 95% CI 0.895-2.624). In a retrospective cohort study evaluating non-immunocompromised patients with CMV reactivation, ganciclovir treatment was not associated with long-term prognosis. Antiviral treatment in this condition would not be necessary unless organ involvement is suspected.</description><identifier>ISSN: 1471-2334</identifier><identifier>EISSN: 1471-2334</identifier><identifier>DOI: 10.1186/s12879-021-06098-4</identifier><identifier>PMID: 33947335</identifier><language>eng</language><publisher>England: BioMed Central</publisher><subject>Antiviral drugs ; Bacterial infections ; Cytomegalovirus ; Disease ; Drug dosages ; Ganciclovir ; Genetic testing ; HIV ; Hospitalization ; Hospitals ; Human immunodeficiency virus ; Illnesses ; Immunocompromised hosts ; Infections ; Length of stay ; Long-term ; Medical prognosis ; Mortality ; Multivariate analysis ; Pathogens ; Patients ; Prognosis ; Reactivation ; Survival ; Ventilators</subject><ispartof>BMC infectious diseases, 2021-05, Vol.21 (1), p.414-414, Article 414</ispartof><rights>2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c496t-e19a237996584662842d7e2c4a333e9d45bc4718bbe3419c10f1cd96a8adc7033</citedby><cites>FETCH-LOGICAL-c496t-e19a237996584662842d7e2c4a333e9d45bc4718bbe3419c10f1cd96a8adc7033</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094573/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2528869448?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25730,27900,27901,36988,36989,44565,53765,53767</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33947335$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Park, Ga Eun</creatorcontrib><creatorcontrib>Ki, Hyun Kyun</creatorcontrib><creatorcontrib>Ko, Jae-Hoon</creatorcontrib><title>Impact of antiviral treatment on long-term prognosis in non-immunocompromised patients with CMV reactivation</title><title>BMC infectious diseases</title><addtitle>BMC Infect Dis</addtitle><description>Reactivation of human cytomegalovirus (CMV) occurs in non-immunocompromised patients with or without specific organ involvement, but it is still unknown whether it has a clinical implication on long-term prognosis or not. A retrospective cohort study evaluating non-immunocompromised adult patients with CMV reactivation was conducted during the period between January 2010 and February 2018. Patients were divided into ganciclovir-treated and non-treated groups. Patients who died within 30 days from CMV reactivation were excluded as they died from complex causes of conditions. Survivors were followed for 30-months to evaluate long-term prognosis. A total of 136 patients with CMV reactivation was included, consisting of 66 ganciclovir-treated (48.5%) and 70 non-treated (51.5%) patients. Overall, patients were old-aged (median 70 years old) and most were treated with pneumonia of any cause (91.2%). More patients in ganciclovir-treated group were treated at intensive care unit (43.9% vs 24.3%, respectively) and had higher viral load over 5000 copies/ml (48.5% vs 22.9%) than non-treated group (all P &lt; 0.05). Primary and secondary endpoints including 30-months survival (28.0 vs 38.9%, respectively) and 12-months survival (40.3% vs 49.2%) were not statistically different between the ganciclovir-treated and non-treated groups. In the multivariate analyses, ganciclovir treatment was not associated with 30-months survival (HR 1.307, 95% CI 0.759-2.251) and 12-months survival (HR 1.533, 95% CI 0.895-2.624). In a retrospective cohort study evaluating non-immunocompromised patients with CMV reactivation, ganciclovir treatment was not associated with long-term prognosis. Antiviral treatment in this condition would not be necessary unless organ involvement is suspected.</description><subject>Antiviral drugs</subject><subject>Bacterial infections</subject><subject>Cytomegalovirus</subject><subject>Disease</subject><subject>Drug dosages</subject><subject>Ganciclovir</subject><subject>Genetic testing</subject><subject>HIV</subject><subject>Hospitalization</subject><subject>Hospitals</subject><subject>Human immunodeficiency virus</subject><subject>Illnesses</subject><subject>Immunocompromised hosts</subject><subject>Infections</subject><subject>Length of stay</subject><subject>Long-term</subject><subject>Medical prognosis</subject><subject>Mortality</subject><subject>Multivariate analysis</subject><subject>Pathogens</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Reactivation</subject><subject>Survival</subject><subject>Ventilators</subject><issn>1471-2334</issn><issn>1471-2334</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkk1v1DAQhiMEoqXwBzggS1y4BPyV2L4goRUfKxVxAa7WrDPZepXYwXaK-Pd4u6VqOdmaeefRzKu3aV4y-pYx3b_LjGtlWspZS3tqdCsfNedMKtZyIeTje_-z5lnOB0qZ0tw8bc6EMFIJ0Z0303ZewBUSRwKh-GufYCIlIZQZQy0HMsWwbwummSwp7kPMPhMfSIih9fO8hujiXDuzzziQBYqvc5n89uWKbL7-JBXlKrfWY3jePBlhyvji9r1ofnz6-H3zpb389nm7-XDZOmn60iIzwIUypu-07HuuJR8UcidBCIFmkN3O1cv0bodCMuMYHZkbTA8aBqeoEBfN9sQdIhzskvwM6Y-N4O1NIaa9hVS8m9ACoyhG1JoxIQeHukelHXR1gQ5gOLLen1jLupuxKkKpFj2APuwEf2X38dpqamSnjoA3t4AUf62Yi61WOZwmCBjXbHnHuTBGcFalr_-THuKaQrXqqNK6N1LqquInlUsx54Tj3TKM2mMw7CkYtgbD3gTDyjr06v4ZdyP_kiD-AgR6tcc</recordid><startdate>20210504</startdate><enddate>20210504</enddate><creator>Park, Ga Eun</creator><creator>Ki, Hyun Kyun</creator><creator>Ko, Jae-Hoon</creator><general>BioMed Central</general><general>BMC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7T2</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PIMPY</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20210504</creationdate><title>Impact of antiviral treatment on long-term prognosis in non-immunocompromised patients with CMV reactivation</title><author>Park, Ga Eun ; Ki, Hyun Kyun ; Ko, Jae-Hoon</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c496t-e19a237996584662842d7e2c4a333e9d45bc4718bbe3419c10f1cd96a8adc7033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antiviral drugs</topic><topic>Bacterial infections</topic><topic>Cytomegalovirus</topic><topic>Disease</topic><topic>Drug dosages</topic><topic>Ganciclovir</topic><topic>Genetic testing</topic><topic>HIV</topic><topic>Hospitalization</topic><topic>Hospitals</topic><topic>Human immunodeficiency virus</topic><topic>Illnesses</topic><topic>Immunocompromised hosts</topic><topic>Infections</topic><topic>Length of stay</topic><topic>Long-term</topic><topic>Medical prognosis</topic><topic>Mortality</topic><topic>Multivariate analysis</topic><topic>Pathogens</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Reactivation</topic><topic>Survival</topic><topic>Ventilators</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Park, Ga Eun</creatorcontrib><creatorcontrib>Ki, Hyun Kyun</creatorcontrib><creatorcontrib>Ko, Jae-Hoon</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health &amp; Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health &amp; Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>BMC infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Park, Ga Eun</au><au>Ki, Hyun Kyun</au><au>Ko, Jae-Hoon</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of antiviral treatment on long-term prognosis in non-immunocompromised patients with CMV reactivation</atitle><jtitle>BMC infectious diseases</jtitle><addtitle>BMC Infect Dis</addtitle><date>2021-05-04</date><risdate>2021</risdate><volume>21</volume><issue>1</issue><spage>414</spage><epage>414</epage><pages>414-414</pages><artnum>414</artnum><issn>1471-2334</issn><eissn>1471-2334</eissn><abstract>Reactivation of human cytomegalovirus (CMV) occurs in non-immunocompromised patients with or without specific organ involvement, but it is still unknown whether it has a clinical implication on long-term prognosis or not. A retrospective cohort study evaluating non-immunocompromised adult patients with CMV reactivation was conducted during the period between January 2010 and February 2018. Patients were divided into ganciclovir-treated and non-treated groups. Patients who died within 30 days from CMV reactivation were excluded as they died from complex causes of conditions. Survivors were followed for 30-months to evaluate long-term prognosis. A total of 136 patients with CMV reactivation was included, consisting of 66 ganciclovir-treated (48.5%) and 70 non-treated (51.5%) patients. Overall, patients were old-aged (median 70 years old) and most were treated with pneumonia of any cause (91.2%). More patients in ganciclovir-treated group were treated at intensive care unit (43.9% vs 24.3%, respectively) and had higher viral load over 5000 copies/ml (48.5% vs 22.9%) than non-treated group (all P &lt; 0.05). Primary and secondary endpoints including 30-months survival (28.0 vs 38.9%, respectively) and 12-months survival (40.3% vs 49.2%) were not statistically different between the ganciclovir-treated and non-treated groups. In the multivariate analyses, ganciclovir treatment was not associated with 30-months survival (HR 1.307, 95% CI 0.759-2.251) and 12-months survival (HR 1.533, 95% CI 0.895-2.624). In a retrospective cohort study evaluating non-immunocompromised patients with CMV reactivation, ganciclovir treatment was not associated with long-term prognosis. Antiviral treatment in this condition would not be necessary unless organ involvement is suspected.</abstract><cop>England</cop><pub>BioMed Central</pub><pmid>33947335</pmid><doi>10.1186/s12879-021-06098-4</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1471-2334
ispartof BMC infectious diseases, 2021-05, Vol.21 (1), p.414-414, Article 414
issn 1471-2334
1471-2334
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_a10e3fe881134dce86e78ca5a235aad3
source Publicly Available Content Database (Proquest) (PQ_SDU_P3); NCBI_PubMed Central（免费）
subjects Antiviral drugs
Bacterial infections
Cytomegalovirus
Disease
Drug dosages
Ganciclovir
Genetic testing
HIV
Hospitalization
Hospitals
Human immunodeficiency virus
Illnesses
Immunocompromised hosts
Infections
Length of stay
Long-term
Medical prognosis
Mortality
Multivariate analysis
Pathogens
Patients
Prognosis
Reactivation
Survival
Ventilators
title Impact of antiviral treatment on long-term prognosis in non-immunocompromised patients with CMV reactivation
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-24T07%3A27%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20antiviral%20treatment%20on%20long-term%20prognosis%20in%20non-immunocompromised%20patients%20with%20CMV%20reactivation&rft.jtitle=BMC%20infectious%20diseases&rft.au=Park,%20Ga%20Eun&rft.date=2021-05-04&rft.volume=21&rft.issue=1&rft.spage=414&rft.epage=414&rft.pages=414-414&rft.artnum=414&rft.issn=1471-2334&rft.eissn=1471-2334&rft_id=info:doi/10.1186/s12879-021-06098-4&rft_dat=%3Cproquest_doaj_%3E2528869448%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c496t-e19a237996584662842d7e2c4a333e9d45bc4718bbe3419c10f1cd96a8adc7033%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2528869448&rft_id=info:pmid/33947335&rfr_iscdi=true